
# Selisistat

Cat. No.:	HY-15452		
CAS No.:	49843-98-3		
Molecular Formula:	C <sub>13</sub> H <sub>13</sub> ClN <sub>2</sub> O	)	
Molecular Weight:	248.71		
Target:	Sirtuin		
Pathway:	Cell Cycle/DNA Damage; Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

## SOLVENT & SOLUBILITY

In Vitro	0.	DMSO : ≥ 100 mg/mL (402.07 mM) * "≥" means soluble, but saturation unknown.					
Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	4.0207 mL	20.1037 mL	40.2075 mL		
		5 mM	0.8041 mL	4.0207 mL	8.0415 mL		
	10 mM	0.4021 mL	2.0104 mL	4.0207 mL			
	Please refer to the so	lubility information to select the app	propriate solvent.				
In Vivo	n Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45 Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution			0 >> 45% saline			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (10.05 mM); Clear solution						

BIOLOGICAL ACTIVITY			
Description	Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC <sub>50</sub> of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease <sup>[1][2]</sup> .		
IC <sub>50</sub> & Target	IC50: 123 nM (SirT1) <sup>[2]</sup>		
In Vitro	Selisistat (1-10 $\mu$ M) inhibits the deacetylation activity of both human SirT1 and Drosophila Sir2 in transfected cells <sup>[1]</sup> .		





MCE has not independently confirmed the accuracy of these methods. They are for reference only.
---

In Vivo

Selisistat (5 and 20 mg/kg, PO, daily; transgenic R6/2 mice beginning at 4.5 weeksof age to death) is protective in the R6/2 mouse model of Huntington's disease (HD)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### PROTOCOL

Cell Assay <sup>[2]</sup>	The immortal mouse macrophage cell line RAW264.7 are used. Cells are seeded in 96-well dishes at a density of $3 \times 10^3$ cells/cm <sup>2</sup> and treated with high glucose at the concentrations of 5.6, 11.1, 25 and 30 mM, alone or with SRT1720 (1 $\mu$ M) or Selisistat(10 $\mu$ M) for 24 h. The stock solution of SRT1720 or Selisistat is prepared by dissolving each of them (in powder form) respectively in DMSO yielding a concentration of 100 $\mu$ M and then stored at -80°C. MTT solution (0.5 mg/mL) is then added to each well and cells are incubated for 4 h at 37°C in a 5% CO <sub>2</sub> incubator. Subsequently, the supernatant is removed, the formation of farmazan is solubilized with DMSO and measured at 540 nm with a Bio-Rad Model 680 Plate Reader <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration <sup>[3]</sup>	Mice <sup>[3]</sup> Mice are injected with Resveratrol (RSV) 30mg/kg (4 mL/kg) or equivalent volume of DMSO (Vehicle) (4 mL/kg) intraperitoneally 18 hours pre-sepsis. This dose of RSV in mice is as per documented literature. In one group of mice, RSV pre-treated mice receive Selisistat (10 mg/kg intraperitoneally; 4mL/kg, Vehicle: DMSO) within 10 minutes of cecal ligation and puncture. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- Nat Immunol. 2022 Aug;23(8):1193-1207.
- Cell Metab. 2021 Jan 5;33(1):110-127.e5.
- Mol Cell. 2020 Jul 16;79(2):304-319.e7.
- Acta Pharm Sin B. 27 August 2022.
- Redox Biol. 2024 Jan 3:69:103030.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Smith MR, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet. 2014;23(11):2995-3007.

[2]. Napper AD, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1 [published correction appears in J Med Chem. 2007 Mar 8;50(5):1086]. J Med Chem. 2005;48(25):8045-8054.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA